Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GNC-035 in Advanced Solid Tumors
NCT05039931Phase 1Withdrawn
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Prophylactic Vaccines, Multispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GNC-035 in solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity up to 2 weeks, Maximum Tolerated Dose or Maximum Administered Dose up to 2 weeks and 2 more. Planned start Sep 2021; status: withdrawn.
02
Drugs
GNC-035
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05039931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039931.